ARC
NKTR icon

Absolute Return Capital’s Nektar Therapeutics NKTR Stock Holding History

Absolute Return Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,633
Closed -$891K – 819
2014
Q2 		$891K Buy
+4,633
New +$819K 0.01% 686

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Absolute Return Capital's NKTR Position: Q3 2014 in Review

Absolute Return Capital sold out of Nektar Therapeutics (NKTR) in Q3 2014, closing a stake of 4,633 shares — an estimated $891K sold.

Absolute Return Capital first reported a position in NKTR in Q2 2014 and held it in 1 quarter. The position peaked at $891K in Q2 2014. 145 funds tracked by Wall St. Rank hold NKTR as of Q3 2014.

  • Absolute Return Capital reported no remaining Nektar Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 4,633 Nektar Therapeutics shares in Q3 2014, an estimated $891K.
  • Absolute Return Capital first reported a position in Nektar Therapeutics in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Nektar Therapeutics position peaked at $891K in Q2 2014.
  • 145 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.